Clinical trials: Schizophrenia Disorders
- Condition Schizophrenia Disorders
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Schizophrenia
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
A study to evaluate the efficacy and safety of an experimental drug (SEP-363856) in acutely psychotic adults with schizophrenia
- Trial name
- NCT02969382
- Testing
- SEP-363856
- Where
- 33 sites in United States, Hungary and 3 more
- Volunteers
- 245 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
The purpose of the study is to explore the maintained efficacy, tolerability, and safety of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional…
- Trial name
- NCT00757705
- Testing
- Paliperidone ER
- Volunteers
- 299 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Negative Symptoms in Schizophrenia
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
The goal of this clinical trial is to evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects with Moderate to Severe Negative Symptoms…
- Trial name
- NCT06107803
- Testing
- Roluperidone 64 mg, Olanzapine 10 MG
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Minerva Neurosciences
Schizophrenia
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic…
- Trial name
- NCT02281773
- Testing
- BI 409306 100 mg QD, BI 498306 50 mg QD, BI 498306 25 mg QD
- Where
- 43 sites in United States, Canada and 3 more
- Volunteers
- 518 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Seroquel XR in Adults With Schizophrenia
The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally…
- Trial name
- NCT00852631
- Testing
- Quetiapine fumarate (Seroquel)
- Where
- 3 sites in Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE- EU (NCT01509053)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection, Oral aripiprazole
- Where
- 10 sites in Belgium, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.
- Trial name
- SPECTRUM (NCT00640601)
- Testing
- Quetiapine Fumarate Extended- Release
- Where
- 36 sites in Australia, Canada and 2 more
- Volunteers
- 331 people
- Sponsor
- AstraZeneca
Schizophrenia
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.
- Trial name
- NCT01614912
- Testing
- SM-13496
- Where
- 4 sites in Japan, Malaysia and 2 more
- Volunteers
- 284 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia
A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia
The purpose of this study is to explore the tolerability, safety and efficacy of flexibly dosed paliperidone extended release (ER) among patients with schizophrenia.
- Trial name
- NCT01606228
- Testing
- Paliperidone ER
- Volunteers
- 188 people
- Sponsor
- Janssen Pharmaceutica
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events.
- Trial name
- SHINE (NCT03893825)
- Testing
- TV-46000
- Where
- 90 sites in United States, Bulgaria and 3 more
- Volunteers
- 336 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Metabolic Syndrome, Schizophrenia
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole…
- Trial name
- NCT00508157
- Testing
- Aripiprazole, Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
- Where
- 30 sites in Belgium, Czechia and 7 more
- Volunteers
- 125 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic marker) in auditory sensory gating is demonstrated after administration of TAK-058 and ondansetron compared to placebo in participants with…
- Trial name
- NCT02614586
- Testing
- TAK-058, Ondansetron
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
A clinical study to investigate the effect of an investigational drug as an added medication to an antipsychotic, in adults with schizophrenia, as measured positron emission tomography (PET) imaging .
- Trial name
- NCT04038957
- Testing
- SEP-363856
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
- Trial name
- NCT01677377
- Testing
- Risperidone, RBP-7000
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Indivior Inc.
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.